Drugs / ALN-CIDEB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06836609 | Apr 2025 → May 2027 expected | metabolic dysfunction-associated steatohepatitis | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07631637 | Jul 2026 → Feb 2029 expected | metabolic dysfunction-associated steatohepatitis | Regeneron Pharmaceuticals | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALN-CIDEB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07631637 ↗ |